Arimoclomal fails to meet primary endpoint in phase II/III clinical trial in inclusion body myositis (IBM)

IBM is a rare, progressively debilitating muscle-wasting disease. Arimoclomal is designed to amplify the production of Heat Shock Proteins (HSPs). The study did not meet the primary endpoint of treatment effect on disease progression, measured by the IBM functional rating scale.

Source:

Biospace Inc.